Filter Results:
(1,247)
Show Results For
- All HBS Web
(1,247)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,247)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
- 19 Aug 2002
- Research & Ideas
Here Comes Internet2—Time to Shed Dot Vertigo
The same DVD would take approximately twenty-five hours to download via a standard DSL/cable line (and 170 hours—or more than seven days—via a 56K modem). Genomics and pharmaceuticals are other research arenas that should benefit from the... View Details
Keywords: by Martha Lagace
- 23 Mar 2010
- First Look
First Look: March 23
catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of side effects, with the... View Details
Keywords: Martha Lagace
- 24 Sep 2020
- News
The Race for a Vaccine
headlines, the vaccine sector was a pretty sleepy space. Interest in vaccine development and production had been on the decline for decades. In the 1960s—the triumphant years after Jonas Salk discovered the first polio vaccine—there were 26 View Details
- 01 Sep 2015
- Blog Post
Building a Startup at HBS
prototype which we showcased at HBS and tested out in the NICU to observe its efficacy and nurse uptake. While we each embarked on different paths after the end of first year– from launching a new healthcare venture in Africa, to working at large View Details
- Fast Answer
Transforming Health Care Delivery
Books Books and journal titles on all aspects of the health care, life sciences and pharmaceutical sectors View Details
- 23 May 2000
- Research & Ideas
Minding the Muse: The Impact of Downsizing on Corporate Creativity
pharmaceutical firms that rely on creativity," she says. "Today's fast-changing global markets place increased pressure on companies of every kind to continuously create new products, services, and competitive strategies if they... View Details
Keywords: by Peter K. Jacobs
- 30 Oct 2007
- First Look
First Look: October 30, 2007
Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side... View Details
Keywords: Sean Silverthorne
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Myers, Kyle, and Scott Sawaya. "Myeloma Investment Fund." Harvard Business School Case 625-047, September 2024.
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
- July 2014
- Teaching Note
Vaxess Technologies, Inc.
By: John A. Quelch
- June 2013
- Supplement
Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)
By: Jim Sharpe
This is Video Supplement for Can PACIV (Puerto Rico) Serve European Customers? HBS Case #808099. View Details
Keywords: Entrepreneurial Management; Global Organizations; Service; Hiring; Incentives, Motivation; Joint Ventures; Customer Service Excellence; Customer Relationship Management; Empowerment; International Expansion; Ownership Structure; Culture; Organization Alignment; Growth and Development Strategy; Entrepreneurship; Private Ownership; Globalized Markets and Industries; Globalized Firms and Management; Pharmaceutical Industry; Pharmaceutical Industry; Puerto Rico; United Kingdom
Sharpe, Jim. "Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)." Harvard Business School Video Supplement 813-722, June 2013.
- May 2013
- Supplement
Can PACIV (Puerto Rico) Serve European Customers?
This is the Spreadsheet Supplement HBS Case #808099 (PACIV). Includes Exhibit 1a, Exhibit 1b, Exhibit 1c, Exhibit 1d, Exhibit 1e, Exhibit 1f, Exhibit 5, Exhibit 6, and Exhibit 8. View Details
Keywords: Entrepreneurs; Foreign Subsidiaries; Global Business; International Business; International Entrepreneurial Finance; International Operations; Entrepreneurship; Globalization; International Finance; Operations; Finance; Pharmaceutical Industry; Pharmaceutical Industry; Puerto Rico; United Kingdom; Europe; United States
- November 2011 (Revised February 2012)
- Case
China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise
By: Vicki Sato, Christoph Jaeker and Pooja Mehta Solanki
As the head of the Novartis Institute for Biomedical Research in China, En Li was shepherding a $1 billion R&D investment in China. So far he had been able to attract a large number of Chinese-born but US-trained scientists to play a critical role in establishing the... View Details
Keywords: Globalized Firms and Management; Research; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; China
Sato, Vicki, Christoph Jaeker, and Pooja Mehta Solanki. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School Case 612-048, November 2011. (Revised February 2012.)
- April 2010
- Teaching Note
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
Teaching Note for [607008]. View Details
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- March 2009
- Teaching Note
Proteus Biomedical: Making Pigs Fly (TN)
Teaching Note for [809051]. View Details
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (D)." Harvard Business School Case 603-046, June 2003. (Revised October 2004.)
- June 1999 (Revised June 2000)
- Case
Eckerd Corporation
By: Michael E. Porter and John E. Kelleher
Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details
Keywords: Competition; Alignment; Supply and Industry; Pharmaceutical Industry; Pharmaceutical Industry
Porter, Michael E., and John E. Kelleher. "Eckerd Corporation." Harvard Business School Case 799-141, June 1999. (Revised June 2000.)
- 11 Aug 2003
- Research & Ideas
Cheap, Fast, and In Control: How Tech Aids Innovation
experimentation and are triggering fundamental changes in R&D processes and performance in such fields as integrated circuit design, automotive development, and pharmaceutical drug discovery. Computer modeling and simulation, rapid... View Details
Keywords: by Wendy Guild
- 01 Dec 2003
- News
The Next Big Thing
life-sciences center of the world, by virtue of its unsurpassed “cluster” of world-renowned universities and teaching hospitals; medical-device, biotech, and pharmaceutical companies; financial firms; and skilled workers. “The leadership... View Details